Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Colorectal Neoplasms
Both
Colorectal Neoplasms
Trial Information
Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer
Inclusion Criteria:
Patients- who are determined to start Regorafenib/ STIVARGA treatment
Exclusion Criteria:
- Patients who have previously received Regorafenib/ STIVARGA
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib
Outcome Time Frame:
Up to 6 months
Safety Issue:
Yes
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
16472
NCT ID:
NCT01843400
Start Date:
April 2013
Completion Date:
March 2021
Related Keywords:
- Colorectal Neoplasms
- Regorafenib
- Colorectal Neoplasms
- Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|
